The Latest Cardiac and Vascular News
ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in Lexington, KY treated the patient utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems supported by […]
ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a COVID-19 patient. The publication concludes that catheter ablation “should be […]
Over 400 scientific publications now document clinical benefits of Stereotaxis robotic technology Most recent publication reviews outcomes of 1,003 consecutive robotic procedures at a single center ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced […]
ST. LOUIS, March 10, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019. “The past year was transformative for Stereotaxis with significant progress financially, commercially and […]
ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the robotic navigation of magnetic ablation catheters to treat heart […]
ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis’ positive impact […]
ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Health—the largest healthcare system in the Kansas City region—has launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center […]
Conference Focuses on Role of Digital Technology in Healthcare; David Fischel Named Panelist in Robotics Session ST. LOUIS, Nov. 22, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present […]
ST. LOUIS, Nov. 14, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019. “The third quarter was highlighted by successful reengagement with the capital markets, meaningful progress in our […]
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies. VIVO uses information commonly collected prior to cardiac procedures to identify […]
